DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee

Information source: Johnson & Johnson Consumer and Personal Products Worldwide
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoarthritis of the Knee

Intervention: acetaminophen (Drug); Rofecoxib (Drug); Rofecoxib (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Johnson & Johnson Consumer and Personal Products Worldwide

Official(s) and/or principal investigator(s):
Edwin Kuffner, MD, Study Director, Affiliation: McNeil Consumer Healthcare USA


To compare acetaminophen (Tylenol) with rofecoxib (Viox) for the treatment of Osteoarthritis of the Knee

Clinical Details

Official title: A Four-Week Comparative Study Evaluating Acetaminophen Extended Release (3900 mg/Day) and Rofecoxib (12.5 mg/Day and 25 mg/Day)in the Treatment of Osteoarthritis of the Knee

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Change from Baseline in the Western Ontario and McMaster Universities (WOMAC) pain subscale score at week 4 in the per protocol study population.

Secondary outcome:

Change from Baseline in the WOMAC pain subscale score

Change from baseline in the WOMAC stiffness and physical function subscale scores

Investigator's impression of therapeutic response

Subject's assessment of medication as an analgesic for the study knee joint

Daily pain intensity differences from baseline

Investigator's global impression of therapeutic response

Subject's overall impression of the study medication

Detailed description: An initial screening visit was performed in order to assess subject medical history and the potential eligibility of subjects. Following the initial screening visit, all potential subjects underwent a washout period from their usual arthritis medication and returned to the study center for a baseline visit to verify their eligibility. At the completion of the baseline visit, all eligible subjects were randomly assigned to a treatment group and instructed on the dosing regimen for their assigned study medication. Subjects returned to the study center for follow-up visits after Week 1 and Week 2 of treatment and a final visit after Week 4 of treatment or upon discontinuation from the study.


Minimum age: 40 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Symptomatic idiopathic osteoarthritis of the knee for a minimum of six months

duration requiring treatment with either an analgesic or anti-inflammatory agent on a regular basis (greater than or equal to three days/week) for at least three months.

- A history of osteoarthritis of the knee characterized by pain of at least a moderate


- Demonstrated radiographic evidence of mild to moderate osteoarthritis based on the

Kellgren and Lawrence radiographic entry criteria of grade 2 or 3 osteoarthritis.

- Subjects' physical ability was to be either American College of Rheumatology (ACR)

Function Class I or II

- At the baseline visit, subjects must have reported a maximum pain intensity

experienced over the previous 24 hours of at least moderate on a five-point scale of none(0), mild(1), moderate(2), moderately severe(3), or severe(4) in order to be enrolled in the study. Exclusion Criteria:

- Medical history, physical examinations, or radiographs suggestive of other types of

arthritis, pseudogout, collagen vascular disease or fibromyalgia.

- Medical or psychiatric conditions that may influence absorption, metabolism, or

excretion of the study medications or interfere with interpretation of adverse reactions to the study drug.

- History of allergy, sensitivity, contraindication or non-response to acetaminophen,

rofecoxib, or drugs classified as NSAIDs including aspirin.

- Use of concomitant medications that might interfere with study drug assessments,

including intra-articular corticosteroids.

- Signs of active knee inflammation, morning stiffness of greater than 30 minutes


- Rheumatoid factor quantitative value greater than or equal to 40 IU/mL or a

Westergren erythrocyte sedimentation rate greater than or equal to 40 mm/hour.

- ACR functional class III or IV, or unable to walk without assistive devices.

- Pregnancy, lactation, or expect to become pregnant within one month of study


Locations and Contacts

Additional Information

Starting date: October 1999
Last updated: August 19, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017